CD226 and neoplasm: In view of the expression of CD137 ligand (CD137L) by dendritic cells (42) and by numerous tumor lines (43, 44), CD137 may down-modulate CD226 both in early phases of anti-tumor immune responses and in later phases at the tumor site, respectively.